SGLT2 inhibitors

This research investigates the relationship between serum levels of statins and SGLT2 inhibitors (SGLT2i) when used together in patients with ischemic heart failure. The study aims to understand how these drugs affect cholesterol, LDL, HDL, and triglyceride levels over time. Conducted by Fayoum University's Department of Cardiology, this prospective study involves 90 outpatient participants diagnosed with ischemic heart disease. Participants are divided into three groups of 30 each: one group takes statins, another takes SGLT2i, and the third group takes both medications. Blood samples are collected at the start and after three months to measure serum statin and plasma SGLT2i levels using high-performance liquid chromatography (HPLC). Researchers monitor the impact of each drug on the other and track changes in lipid profiles and any adverse effects. During the study, patients provide informed consent and attend scheduled visits for blood sampling and laboratory tests. The main outcome is to evaluate the combined effect of statin and SGLT2i therapy on ischemic heart disease after three months. Safety and side effects are also observed. The study spans from April to July 2024, ensuring detailed monitoring of participants' responses to the treatments.

Researchers are evaluating QX1206 in an open-label phase 1b trial involving adults with Type 2 Diabetes Mellitus (T2DM) and Non-Alcoholic Fatty Liver Disease (NAFLD). The study aims to determine the recommended dose for future studies and examine the preliminary effects of QX1206 on blood sugar control and other metabolic factors. Participants will take QX1206 orally before bedtime. The trial will last up to 12 weeks, during which laboratory tests and measurements will be taken before the first dose and throughout the study to monitor effects and safety. The study focuses on finding the best dose and assessing changes in blood sugar and insulin resistance. During the study, participants will undergo regular assessments including blood tests for hemoglobin A1c, fasting glucose, insulin levels, and insulin resistance. Researchers will track the recommended phase 2 dose from day 1 through week 12. Patients must comply with study procedures and attend all visits. The total participation period is up to 12 weeks.

Researchers are evaluating the efficacy and safety of BGM0504 compared to semaglutide in people with type 2 diabetes who are already taking metformin and/or sulfonylureas. This phase 3 trial is conducted in China and sponsored by BrightGene Bio-Medical Technology Co., Ltd. The goal is to see how well these treatments control blood sugar levels and manage the condition. Participants receive one of three treatments: 5 mg or 10 mg of BGM0504, or 1 mg of semaglutide. All drugs are given as weekly injections under the skin. The trial includes a 32-week period to measure blood sugar changes, followed by further assessments up to 52 weeks to evaluate body weight, blood sugar control, and fasting glucose levels. During the study, participants will have regular visits for blood tests to measure hemoglobin A1c and fasting glucose, along with weight checks. Researchers will monitor safety and treatment effects throughout the study. The total participation time can last up to 52 weeks, with ongoing evaluations to understand how the treatments work over time.

Researchers are evaluating the effects of BGM0504 in Chinese patients with type 2 diabetes who have poor blood sugar control managed only by diet and exercise. This phase III clinical trial aims to assess the benefits and safety of BGM0504 injections over 32 weeks compared to a placebo, with extended monitoring for up to 52 weeks to evaluate longer-term effects. Participants receive weekly subcutaneous injections of either 5 mg or 10 mg of BGM0504, or a placebo, in a randomized and double-blind manner. The study includes a main treatment period of 32 weeks, during which the primary outcome of blood sugar control (measured by hemoglobin A1c) is evaluated, followed by continued treatment and assessment up to 52 weeks for additional safety and efficacy measures. During the trial, participants will undergo regular assessments including blood tests to measure hemoglobin A1c, fasting glucose, and body weight. These evaluations occur at specified intervals to monitor changes from baseline. Safety and treatment adherence will also be closely followed throughout the study period, which lasts up to 52 weeks for each participant.

Researchers are studying the safety, tolerability, and effects of ALN-4324 in overweight to obese adults. The study has two parts: one in healthy volunteers and another in adults with type 2 diabetes mellitus (T2DM). It aims to understand how the drug behaves in the body and its impact on blood sugar control and other health measures. Participants in the first part receive a single dose of ALN-4324 or a placebo, given as an injection under the skin. In the second part, adults with T2DM receive multiple doses of ALN-4324 or placebo, also by injection. The study uses a randomized, double-blind design, meaning participants are randomly assigned to groups and neither they nor the researchers know who receives the drug or placebo during the trial. During the study, participants will be monitored for side effects and how their bodies process the drug. Blood tests will measure drug levels and effects on blood sugar control, including hemoglobin A1c and glucose tolerance. The study lasts up to 12 months, with assessments at various times depending on the part. Safety and how well participants tolerate the drug are the main outcomes being measured.

Researchers are studying the effects of a single dose of ALN-4324 on whole-body insulin sensitivity in adults with Type 2 Diabetes Mellitus (T2DM). This phase 2, randomized, double-blind, placebo-controlled trial aims to assess how well ALN-4324 works compared to a placebo in improving insulin sensitivity, which is important for managing blood sugar in T2DM patients. Participants will receive either one subcutaneous injection of ALN-4324 or a matching placebo. The study is designed with two groups, and each participant only receives a single dose. The trial includes a follow-up period lasting up to 9 months to monitor effects and safety. During the study, participants will be evaluated through various assessments including changes in insulin sensitivity measured by the M-value and M/I ratio, endogenous glucose production, and Hemoglobin A1c levels. Researchers will also track the frequency of adverse events for safety. These measurements will be taken from baseline and followed for up to 6 months, with some safety monitoring extending to 9 months after dosing.

Researchers are investigating how biological aging relates to the risk of developing type 2 diabetes mellitus (T2DM), especially in people with and without metabolic dysfunction-associated steatotic liver disease (MASLD). They are measuring biological age using methods like phenotypic age, Klemera-Doubal method, and homeostatic dysregulation to see how aging affects diabetes risk. This observational study evaluates these associations using various statistical models to better understand the link between aging and T2DM incidence over time. Participants are grouped based on whether they have MASLD at the start of the study or not. The study collects data from annual health check-ups, including abdominal ultrasound and metabolic indicators like body mass index, blood pressure, cholesterol levels, and blood sugar measurements. No experimental treatments are given, as this is an observational study monitoring participants over an average of three years. During the study, researchers will track the onset of type 2 diabetes by reviewing health records and metabolic data collected yearly. They will assess the incidence of T2DM and analyze how biological aging measures correspond with disease development. The primary outcome is the incidence of new T2DM cases through the study completion. Participants will be observed for about three years, with no interventions applied, allowing researchers to monitor natural disease progression and aging effects.

This research focuses on adults with type 2 diabetes mellitus (T2DM) to evaluate how screening for diabetes distress and related interventions affect patients. Diabetes distress, which is the stress and worry related to managing diabetes, is common and linked to poorer self-care and health outcomes. The study aims to improve diabetes care for diverse populations, especially in community health centers that care for many racial and ethnic minorities. Participants will be involved in one of two study groups. One group will receive detailed training on the ARISE program, a structured approach to screen for diabetes distress and address it using personalized strategies and referrals. The other group will receive a brief training on a general diabetes distress screening model. The study compares these approaches through a cluster randomized controlled trial involving community health centers. Throughout the 12 months of the study, researchers will monitor blood sugar control (A1C levels), diabetes distress scores, cholesterol, blood pressure, body mass index, depression and anxiety screenings, and the number of referrals made. The study includes regular assessments and tracks changes over time to understand the impact of these screening and intervention strategies on patient health and emotional well-being.

Researchers are evaluating the safety and effectiveness of Henagliflozin in Chinese adults with type 2 diabetes mellitus (T2DM). This observational study aims to monitor how this medication impacts metabolic parameters like blood sugar levels, blood pressure, and body weight, as well as its side effects. The study also explores how Henagliflozin affects muscle health, including muscle mass and strength, in real-world use. Participants will receive Henagliflozin as part of their usual care, and the study involves observing these patients without changing their treatment. The main focus is to track adverse events and serious side effects over a 24-week treatment period. Researchers will also assess changes in glycated hemoglobin (HbA1c), fasting plasma glucose, post-meal glucose, blood pressure, weight, and muscle health markers during this time. Throughout the 24 weeks, participants will be monitored regularly for safety and treatment effects. Data on adverse events, metabolic changes, and muscle health will be collected to understand the medication's impact. The study is sponsored by the Second Affiliated Hospital of Guangxi Medical University and is planned to start in June 2025, with the final results expected by September 2026.

Researchers are investigating pancreatic function in adults with type 2 diabetes to better understand both hormone production and digestive processes. This observational study aims to identify whether pancreatic problems can help detect pancreatogenic diabetes and how blood markers and pancreas structure relate to pancreatic function. The study is conducted as a cross-sectional, single-region, multisite investigation in outpatient clinics in the Aktobe region, Kazakhstan, focusing on adults with type 2 diabetes diagnosed within the past five years. Participants will attend a single visit during which blood tests will measure glucose, insulin, and other relevant markers. They will provide a stool sample to evaluate digestive function and undergo ultrasound imaging of the pancreas. Additionally, participants will answer questions about digestive symptoms to assess pancreatic exocrine function. The study groups include adults with type 2 diabetes who do not have exocrine pancreatic insufficiency based on fecal elastase-1 levels or questionnaire results. During the visit, researchers will collect and analyze various biochemical and imaging data, including fecal elastase-1, pancreatic ultrasound parameters, and blood markers such as C-peptide and glycated hemoglobin. Outcome measures will focus on the prevalence of pancreatogenic diabetes at the baseline visit. The study does not involve treatment but aims to improve diagnostic understanding through these comprehensive assessments. Total participation involves this single outpatient visit with no further follow-up required.